What are the key takeaways from this Huberman Lab episode?

Key insights include: **Stanford Neuromodulation Therapy (SNT):** By applying TMS every hour for ten hours across five consecutive days, Williams' protocol delivers the equivalent of seven and a half months of standard TMS treatment. This spaced-learning approach produces full mood remission in 60–90% of patients within one to five days, with some maintaining remission for four or more years.; **MDMA for PTSD:** In clinical trials using 75–150mg MDMA administered one to two times under physician supervision, approximately two-thirds of PTSD patients achieved clinically significant symptom reduction. Effects lasted years in follow-up studies, compared to ketamine infusions, which average only ten days of relief per session before repeat dosing is required.; **Psilocybin for Depression:** Open-label psilocybin trials show 50–67% of patients achieving remission from depression; blinded controlled trials show roughly one-third responding. Both psilocybin and SNT produce the same measurable brain change: reduced connectivity between the negatively valenced subgenual anterior cingulate and the default mode network, suggesting a shared therapeutic mechanism.

What did Nolan Williams discuss on Huberman Lab?

Dr. Nolan Williams, Stanford neurologist-psychiatrist, explains how transcranial magnetic stimulation and psychedelics like psilocybin, MDMA, and ibogaine rewire depression and PTSD circuits. Both approaches target the same subgenual anterior cingulate-default mode network connection, producing remission in days without drugs remaining in the system. Key topics include: **Stanford Neuromodulation Therapy (SNT):** By applying TMS every hour for ten hours across five consecutive days, Williams' protocol delivers the equivalent of seven and a half months of standard TMS treatment. This spaced-learning approach produces full mood remission in 60–90% of patients within one to five days, with some maintaining remission for four or more years.; **MDMA for PTSD:** In clinical trials using 75–150mg MDMA administered one to two times under physician supervision, approximately two-thirds of PTSD patients achieved clinically significant symptom reduction. Effects lasted years in follow-up studies, compared to ketamine infusions, which average only ten days of relief per session before repeat dosing is required..

How long is this episode of Huberman Lab?

This episode is 40 minutes long. SignalCast provides an AI-generated summary so you can get the key insights in about 3 minutes.

Huberman Lab

Essentials: Psychedelics & Neurostimulation for Brain Rewiring | Dr. Nolan Williams

June 4, 2026

40 min episode · 2 min read

Nolan Williams

Episode

40 min

Read time

2 min

Topics

Crypto & Web3, Psychology & Behavior, Philosophy & Wisdom

AI-Generated Summary

Published Jun 4, 2026

Key Takeaways

✓Stanford Neuromodulation Therapy (SNT): By applying TMS every hour for ten hours across five consecutive days, Williams' protocol delivers the equivalent of seven and a half months of standard TMS treatment. This spaced-learning approach produces full mood remission in 60–90% of patients within one to five days, with some maintaining remission for four or more years.
✓MDMA for PTSD: In clinical trials using 75–150mg MDMA administered one to two times under physician supervision, approximately two-thirds of PTSD patients achieved clinically significant symptom reduction. Effects lasted years in follow-up studies, compared to ketamine infusions, which average only ten days of relief per session before repeat dosing is required.
✓Psilocybin for Depression: Open-label psilocybin trials show 50–67% of patients achieving remission from depression; blinded controlled trials show roughly one-third responding. Both psilocybin and SNT produce the same measurable brain change: reduced connectivity between the negatively valenced subgenual anterior cingulate and the default mode network, suggesting a shared therapeutic mechanism.
✓Circuit Model Replaces Chemical Imbalance: Depression is not a serotonin deficit but a dysregulated prefrontal-cingulate circuit where the left dorsolateral prefrontal cortex fails to govern the conflict-detection system. TMS works by exogenously restoring that top-down regulation without altering serotonin, reframing depression as a correctable electrophysiological arrhythmia rather than a permanent chemical or psychological deficit.
✓Ibogaine for Moral Injury and PTSD: Ibogaine, extracted from African iboga root bark, produces a 24–36 hour closed-eye life-review experience that special operations veterans describe as enabling self-forgiveness for combat-related moral injury. Williams' ongoing first-in-human neurobiological study measures pre- and post-treatment depression scales, PTSD scales, neurocognitive batteries, neuroimaging, and EEG to quantify these effects systematically.

What It Covers

Dr. Nolan Williams, Stanford neurologist-psychiatrist, explains how transcranial magnetic stimulation and psychedelics like psilocybin, MDMA, and ibogaine rewire depression and PTSD circuits. Both approaches target the same subgenual anterior cingulate-default mode network connection, producing remission in days without drugs remaining in the system.

Key Questions Answered

•Stanford Neuromodulation Therapy (SNT): By applying TMS every hour for ten hours across five consecutive days, Williams' protocol delivers the equivalent of seven and a half months of standard TMS treatment. This spaced-learning approach produces full mood remission in 60–90% of patients within one to five days, with some maintaining remission for four or more years.
•MDMA for PTSD: In clinical trials using 75–150mg MDMA administered one to two times under physician supervision, approximately two-thirds of PTSD patients achieved clinically significant symptom reduction. Effects lasted years in follow-up studies, compared to ketamine infusions, which average only ten days of relief per session before repeat dosing is required.
•Psilocybin for Depression: Open-label psilocybin trials show 50–67% of patients achieving remission from depression; blinded controlled trials show roughly one-third responding. Both psilocybin and SNT produce the same measurable brain change: reduced connectivity between the negatively valenced subgenual anterior cingulate and the default mode network, suggesting a shared therapeutic mechanism.
•Circuit Model Replaces Chemical Imbalance: Depression is not a serotonin deficit but a dysregulated prefrontal-cingulate circuit where the left dorsolateral prefrontal cortex fails to govern the conflict-detection system. TMS works by exogenously restoring that top-down regulation without altering serotonin, reframing depression as a correctable electrophysiological arrhythmia rather than a permanent chemical or psychological deficit.
•Ibogaine for Moral Injury and PTSD: Ibogaine, extracted from African iboga root bark, produces a 24–36 hour closed-eye life-review experience that special operations veterans describe as enabling self-forgiveness for combat-related moral injury. Williams' ongoing first-in-human neurobiological study measures pre- and post-treatment depression scales, PTSD scales, neurocognitive batteries, neuroimaging, and EEG to quantify these effects systematically.

Notable Moment

Williams describes patients who achieve full remission mid-week during the five-day SNT protocol spontaneously reporting their first-ever experience of present-moment awareness — something they had read about in mindfulness literature but never accessed — without any instruction or suggestion from clinical staff beforehand.

Know someone who'd find this useful?

Episode Transcript

Welcome to Huberman Lab Essentials, where we revisit past episodes for the most potent and actionable science based tools for mental health, physical health, and performance. I'm Andrew Huberman, and I'm a professor of neurobiology and ophthalmology at Stanford School of Medicine. And now for my discussion with Doctor. Nolan Williams. Thanks for joining today. I'm really excited to have this conversation. I have a lot of questions about different compounds, psychedelics in particular. Yeah. But before we get into that discussion, I want to ask you about depression broadly speaking. Sure. I heard you say in a wonderful talk that you gave that depression is perhaps the most debilitating condition worldwide, yet in contrast to other medical conditions like like cancer, we actually have a fairly limited number of tools to approach depression. And yet, number of tools and the potency of those tools is growing. Depression is, the most disabling condition worldwide. What's interesting about depression is it's both a risk factor, for other illnesses, and it makes other medical and psychiatric illnesses worse. Right? So recently, the American Heart Association added depression as the fourth major risk factor for coronary artery disease. Right? So alongside the the risk factors that we know, hypertension, high blood pressure, hyperlipidemia, high cholesterol, and diabetes, you know, high blood sugar, those three have been on the list for a long time, and depression and, you know, being added to the list is the fourth one. A lot of what we're doing in the lab actually is, is measuring kind of brain heart connections. And we can actually with transcranial magnetic stimulation, a form of brain stimulation, we can actually decelerate the heart rate and capture that heart rate deceleration over the mood regulatory regions. And so, actually a direct probe of that connection. We've been very interested in a very particular clinical set of problems around the the most severe and the most high acuity settings that, folks with depression end up being in. And that's in, you know, emergency settings where they go into inpatient units. The field really hasn't developed a way of, you know, of consistently being able to treat that problem, and folks end up getting the same standard oral antidepressants that they've been getting outpatient. And and I came to this because, you know, dual trained as a neurologist and psychiatrist, went back and forth between neurology and psychiatry, saw that in neurology, we have all of these ways of treating acute brain based problems and really wanted to emulate that in psychiatry and find ways to develop and engineer new, you know, brain based solutions. Many people out there probably think of the relationship between the the heart and the mind as kind of woo or kind of a soft biology. But here, you're talking about an actual physical connection. Yep. What area of the brain is it? Yeah. The first place where the stimulation goes is called the dorsolateral prefrontal cortex. It's kind of …

Get the full transcript (7,193 words) + summary by email — free

One-time email with the complete transcript and AI summary of this episode. No account needed.

One email, no spam. We’ll also show you what SignalCast does.

Browse all Huberman Lab transcripts →